Skip to main content
. 2020 Nov 19;11:597985. doi: 10.3389/fphar.2020.597985

TABLE 3.

Clinical trials against HCQ use. The following databases were searched: Cochrane, Embase, Medline, New England Journal of Medicine and PubMed. A total of four trials (two randomized controlled trials (RCT) and two cohort studies) showed no significant improvement in clinical outcome and mortality when comparing the HCQ-treated group to the control group.

Evidence against the use of HCQ
Study Study type Country Population size Results Ref
A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19) Single-center RCT China 30 No significant prognostic difference was noted between the HCQ-treated group and the control group.Comparable adverse events were experienced by each group. Studied outcomes included: • Time to negative conversion • time for body temperature normalization • radiological progression• adverse events experienced by both groups (Chen J. et al., 2020)
Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: Open label, randomised controlled trial Multi-center RCT China 150 No significant prognostic difference was noted between the HCQ-treated group and the control group. More adverse events were observed in the treated group.Studied outcomes included: • Time to negative conversion • adverse events experienced by both groups (Tang et al., 2020)
Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York state Multi-center retrospective cohort study United States, New York 1,438 There was no significant improvement in mortality rate in hospitalized COVID-19 patients treated with HCQ, azithromycin or HCQ + azithromycin. Studied outcomes included: • In-hospital mortality • incidence of fatal cardiac events (Rosenberg et al., 2020)
Observational study of hydroxychloroquine in hospitalized patients with Covid-19 Single-center, observational study United States, New York 1,446 The use of HCQ had no significant effect on clinical outcomes and in-hospital mortality.Studied outcomes included: • Clinical worsening (denoted by the need for intubation) • death (Geleris et al., 2020)